Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suga, S.-i.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suga, S.-i.
Right arrow Articles by Johnson, R. J.
J Am Soc Nephrol 14:397-406, 2003
© 2003 American Society of Nephrology

Endothelin A Receptor Blockade and Endothelin B Receptor Blockade Improve Hypokalemic Nephropathy by Different Mechanisms

Shin-ichi Suga*, Naomi Yasui*, Fumiki Yoshihara{dagger}, Takeshi Horio{dagger}, Yuhei Kawano{dagger}, Kenji Kangawa* and Richard J. Johnson{ddagger}

*National Cardiovascular Center Research Institute, {dagger}Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan; and {ddagger}Baylor College of Medicine, Houston, Texas.

Correspondence to Dr. Shin-ichi Suga, Division of Hypertension, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. Phone: 81-6-6833-5012, ext. 2471; Fax: 81-6-6872-8091;

ABSTRACT. Hypokalemia causes renal tubulointerstitial injury with an elevation in renal endothelin-1 (ET-1). It was hypothesized that hypokalemic tubulointerstitial injury is ameliorated by the blockade of ET-A receptors (ETA), whereas ET-B receptor (ETB) antagonism may exacerbate the injury, because ETB is thought to mediate vasodilation. Rats were fed a K+-deficient diet alone (LC) or with an ETA-selective antagonist ABT-627 (LA) or an ETB-selective antagonist A-192621 (LB) for 8 wk. Control rats were on a normal K+ diet alone or with the ETA-selective or ETB-selective antagonists. The severity of hypokalemia was not significantly different among LA, LB, and LC. LC developed tubulointerstitial injury with an elevation of renal preproET-1 mRNA level. There was an increase in tubular osteopontin expression, macrophage infiltration, collagen accumulation, and tubular cell hyperplasia. ETA blockade significantly ameliorated all parameters for renal injury in the cortex without suppressing local ET-1 and ETA expression. By contrast, ETB blockade significantly reduced local ET-1 and ETA expression and improved the injury to a similar extent in the cortex. In the medulla, ETA or ETB blockade only partially blocked renal injury. ETA blockade did not affect BP in normokalemic or hypokalemic rats. ETB blockade induced a BP elevation with a decrease in urinary Na+ excretion in normokalemic but not in hypokalemic rats. These results indicate that ET-1 can mediate hypokalemic renal injury in two different ways: by directly stimulating ETA and by locally promoting endogenous ET-1 production via ETB. Thus, ETA as well as ETB blockade may be renoprotective in hypokalemic nephropathy. E-mail: ssuga@ri.ncvc.go.jp




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
S. Reungjui, C. A. Roncal, W. Sato, O. Y. Glushakova, B. P. Croker, S.-i. Suga, X. Ouyang, K. Tungsanga, T. Nakagawa, R. J. Johnson, et al.
Hypokalemic Nephropathy is Associated with Impaired Angiogenesis
J. Am. Soc. Nephrol., January 1, 2008; 19(1): 125 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Goddard, N. R. Johnston, A. D. Cumming, and D. J. Webb
Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade
Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1433 - F1438.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M.-Y. Chang, E. Parker, M. El Nahas, J. L. Haylor, and A. C.M. Ong
Endothelin B Receptor Blockade Accelerates Disease Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 560 - 569.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. M. Sasser, J. C. Sullivan, J. L. Hobbs, T. Yamamoto, D. M. Pollock, P. K. Carmines, and J. S. Pollock
Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory Mechanism
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 143 - 154.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Makino, Y. Miyamoto, K. Sawai, K. Mori, M. Mukoyama, K. Nakao, Y. Yoshimasa, and S.-i. Suga
Altered Gene Expression Related to Glomerulogenesis and Podocyte Structure in Early Diabetic Nephropathy of db/db Mice and Its Restoration by Pioglitazone.
Diabetes, October 1, 2006; 55(10): 2747 - 2756.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
N. Dhaun, J. Goddard, and DavidJ. Webb
The Endothelin System and Its Antagonism in Chronic Kidney Disease
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673